Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, has commenced an investigator-initiated multi-center Phase II clinical trial of Allocetra (formerly referred to as off-the-shelf Allocetra) in COVID-19 patients.   The COVID-19 study is a multi-center investigator-initiated, Phase II clinical trial. The trial is expected to recruit up to five patients in each participating center and is designed to assess Allocetra in combination with standard of care therapy in patients with C...